Trial Profile
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms MYELAXAT
- 10 Sep 2017 Status changed from active, no longer recruiting to completed.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Status changed to active, no longer recruiting as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology